Yes, and this is one of the clearest, least-debated areas in the entire field.

Menopause before about 45, and especially before 40, is consistently linked with higher cardiovascular and mortality risk across large studies. Because of this, guidelines treat hormone therapy for women with premature or early menopause as replacement, not optional symptom treatment - it is recommended until at least the natural age of menopause unless there is a specific reason not to. This population also typically needs higher, full-replacement doses rather than standard menopausal doses.

What to know about this answer

There is essentially no expert disagreement on this question - guidelines, cardiovascular epidemiology, and field clinicians all point the same direction. The remaining problem is not scientific dispute but a real-world access and communication gap for this group of women.

What the research shows, and which source each finding rests on

Meta-analysis of 32 studies (310,329 women): menopause before 45 versus at or after 45 carried coronary heart disease RR 1.50 (1.28-1.76), cardiovascular mortality RR 1.19, and all-cause mortality RR 1.12.

A[1]

Pooled individual-level data from 15 cohorts (301,438 women): premature menopause (before 40) carried HR 1.55 for a first non-fatal cardiovascular event; early menopause (40-44) carried HR 1.30.

A[2]

UK Biobank: premature natural menopause HR 1.36, and surgical premature menopause HR 1.87, for composite cardiovascular disease, adjusted for hormone therapy use.

C[3]

Bilateral removal of both ovaries before age 45 without estrogen replacement through age 45 was associated with mortality HR 1.67 (1.16-2.40).

C[4]

The 2024 ESHRE/ASRM/IMS evidence-based premature ovarian insufficiency guideline (145 recommendations) recommends hormone therapy to mitigate bone, cardiovascular, cognitive, and quality-of-life consequences.

A[5]

NICE NG23 recommends starting hormonal treatment, either hormone therapy or a combined hormonal contraceptive, and continuing it until at least the age of natural menopause, unless contraindicated.

A[6]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

The science is settled; access to it is not

field clinicians in the corpus, including Dr. Corinne Menn, who herself experienced medically induced early menopause

Guidelines are unambiguous on this point, but the real failure described by clinicians is that women plunged into premature menopause often describe an information vacuum, being told they need full higher-dose replacement that isn't standard menopausal hormone therapy, with nowhere to go for guidance.

A[5]A[6]

What would settle it: Nothing further is needed on whether hormone therapy is indicated for this group; what would help is better systematic identification and referral pathways so fewer women fall through the gap.

What is really going on here

  1. I went through menopause before 45, or had my ovaries removed - am I on full replacement dosing until at least age 51, as guidelines require, or was I given a standard low menopausal dose, or nothing?

Questions for your doctor

  1. Given that I went through menopause before 45, or had my ovaries removed, am I on a full-replacement dose, not a standard menopausal dose?
  2. Is the plan to continue hormone therapy until at least age 51, the average natural age of menopause?
  3. What is being done to protect my bone and cardiovascular health specifically because of my age at menopause?
  4. If I can't or don't want to take hormone therapy, what alternative plan addresses these same risks?

Questions with no answer yet

Does starting full-replacement-dose hormone therapy immediately after early or surgical menopause actually restore dementia and cardiovascular risk to the same level as women who reached menopause at the average age, or does it only partially reduce the added risk?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The recommendation to treat until at least the natural age of menopause is grounded in observational data connecting early estrogen loss to higher risk, and in the logic of replacing what would otherwise still be present. No randomized trial has measured whether treated early-menopause women actually end up at the same risk level as women with average-age natural menopause, as opposed to simply a lower risk than untreated early-menopause women.

What would test it: A long-term comparison of treated early- or surgical-menopause women, average-age natural-menopause women, and untreated early- or surgical-menopause women, with cardiovascular and cognitive outcomes tracked into older age.

How large is the real-world gap between the guideline-recommended full-replacement dose and what women with early or surgical menopause are actually prescribed?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Clinicians in this field describe an information vacuum in which women who need full higher-dose replacement report being given standard, lower menopausal doses or nothing at all, but this has not been measured as a systematic dosing-gap statistic the way documentation and treatment rates have been measured for menopause in general.

What would test it: A records-based study specifically identifying women with a diagnosis of early or surgical menopause and comparing their actual prescribed dose against the guideline-recommended full-replacement standard.

Sources

  1. 1.Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis.Muka T, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes... and all-cause mortality. JAMA Cardiol. 2016;1(7):767-776. · Systematic review or guideline
  2. 2.Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data.Zhu D, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553-e564. · Systematic review or guideline
  3. 3.Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.Honigberg MC, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411-2421. · Observational study
  4. 4.Survival patterns after oophorectomy in premenopausal women: a population-based cohort study.Rocca WA, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821-8. · Observational study
  5. 5.Evidence-based guideline: premature ovarian insufficiency.Panay N, et al. Evidence-based guideline: premature ovarian insufficiency (ESHRE/ASRM/IMS/CRE-WHiRL). Hum Reprod Open. 2024;2024(4):hoae065. · Systematic review or guideline
  6. 6.NICE guideline NG23. Menopause: identification and management. November 2024 update, recommendation 1.7.7.Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides